Reckamp, Karen L <br/><br/>
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Feb 2008 
 - 117-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e3181622bef  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Biomarkers, Tumor--blood<br/>Cadherins--blood<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Celecoxib<br/>Chemokines, CC--blood<br/>Cyclooxygenase Inhibitors--pharmacology<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Macrophage Inflammatory Proteins--blood<br/>Matrix Metalloproteinase 9--blood<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyrazoles--administration & dosage<br/>Quinazolines--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Tissue Inhibitor of Metalloproteinase-1--blood